Neurosense Therapeutics Ltd (NRSN)

NASDAQ
Currency in USD
1.320
+0.040(+3.13%)
Closed·
After Hours
1.310-0.010(-0.758%)
·
NRSN Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 12 days
Fair Value
Day's Range
1.2501.340
52 wk Range
0.5121.500
Key Statistics
Edit
Prev. Close
1.26
Open
1.29
Day's Range
1.25-1.34
52 wk Range
0.512-1.5
Volume
284.19K
Average Volume (3m)
153.92K
1-Year Change
5.18%
Book Value / Share
0.11
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NRSN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
10.750
Upside
+714.39%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Neurosense Therapeutics Ltd Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer’s disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

Compare NRSN to Peers and Sector

Metrics to compare
NRSN
Peers
Sector
Relationship
P/E Ratio
−3.1x−1.8x−0.5x
PEG Ratio
−0.12−0.020.00
Price/Book
12.2x1.7x2.6x
Price / LTM Sales
-38.3x2.9x
Upside (Analyst Target)
-520.2%45.8%
Fair Value Upside
Unlock14.5%8.6%Unlock

Analyst Ratings

2 Buy
1 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 10.750
(+714.39% Upside)

Earnings

Latest Release
Apr 08, 2025
EPS / Forecast
-0.54 / -0.08
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

FAQ

What Is the Neurosense Therapeutics (NRSN) Stock Price Today?

The Neurosense Therapeutics stock price today is 1.32

What Stock Exchange Does Neurosense Therapeutics Trade On?

Neurosense Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Neurosense Therapeutics?

The stock symbol for Neurosense Therapeutics is "NRSN."

What Is the Neurosense Therapeutics Market Cap?

As of today, Neurosense Therapeutics market cap is 30.23M.

What Is Neurosense Therapeutics's Earnings Per Share (TTM)?

The Neurosense Therapeutics EPS (TTM) is -0.55.

When Is the Next Neurosense Therapeutics Earnings Date?

Neurosense Therapeutics will release its next earnings report on 27 May 2025.

From a Technical Analysis Perspective, Is NRSN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.